Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

WORCESTER, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), announced on June 27, 2007 blinded interim data from the start of its fast-tracked pivotal Phase 3 clinical trial of BiovaxID(TM) for Non-Hodgkin's lymphoma (NHL) from September 2000 through June 2006. This interim blinded data is the most recent data that has been made available to the Company prior to its latest meeting with the Data Monitoring Committee for the ongoing Phase 3 study. The interim blinded data covers 122 patients who have received either BiovaxID or control vaccine. Randomization was 2:1 in favor of BiovaxID. The blinded data in a Kaplan Meier disease-free survival curve for the per-protocol treatment group in the trial showed that approximately 40% of the evaluable patients in the study remained disease-free from 40 months to almost 70 months.

Dr. Steve Arikian, Biovest Chairman and Chief Executive Officer, stated, "Biovest believes these results are consistent with the expected efficacy of BiovaxID vs. control. Moreover, BiovaxID has the longest Phase 3 follow-up data for patients receiving an active immunotherapy for follicular Non-Hodgkin's Lymphoma of any of the Phase 3 Non-Hodgkin's Lymphoma immunotherapy trials ongoing today. We are greatly encouraged by the blinded interim data presented at the Jeffries Healthcare Conference on June 27th, 2007."

BiovaxID is an anti-cancer vaccine undergoing testing in a Fast-Tracked pivotal Phase 3 clinical trial for a target indication of Non-Hodgkin's Lymphoma. BiovaxID is a personalized, patient-specific vaccine designed to stimulate the patient's own immune system to recognize and destroy residual cancerous B-cells that remain after the patient has undergone chemotherapy. Unlike many other approaches to treating NHL, BiovaxID is designed to target only cancerous B-cells.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... , ... June 30, 2015 , ... According to a ... 2007 to 2013 while heroin-related deaths more than tripled in the same period—leading a ... Novus Medical Detox Center , a leading Florida-based drug treatment facility, asserts that ...
(Date:6/30/2015)... ... 30, 2015 , ... ADVOCATE, the premier provider of radiology ... exclusive billing agreements with Jackson Radiology Associates in Jackson, TN. , ... of billing process software functionality called Experience Based Technology (EBTTM). EBTTM improves ...
(Date:6/30/2015)... ... ... On June 26, 2015, Harper’s Bazaar Magazine in an article titled “5 ... not expect to cause acne flare-ups. The list includes pillowcases, cell phones, ... are clogged pores and bacteria and each of the named triggers unexpectedly creates a ...
(Date:6/30/2015)... Jacksonville, FL (PRWEB) , ... June 30, 2015 ... ... in Jacksonville, reported today it has more than doubled the size of its ... , The center’s medical staff -- which includes physicians, nurse practitioners and physician ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... 26th Annual Alzheimer's Association of Colorado's Education Symposium on November 9, 2015 at ... is honored to host a conversation with Kim and Ashley Campbell, the wife ...
Breaking Medicine News(10 mins):Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 2Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 3Health News:Novus Medical Detox Center Urges Education and Action as New DEA Report Reveals Rising Heroin Use and Deaths 4Health News:ADVOCATE Wins Billing Agreements with Jackson Radiology Associates 2Health News:A List of 5 Surprising Acne Triggers and the Latest Acne Treatment Options 2Health News:Lakeview Health, a Nationally Recognized Drug Rehabilitation Center in Florida, Doubles Size of Medical Staff 2Health News:Family of Singer Glen Campbell to Discuss Living with Dementia at the Alzheimer's Association of Colorado's 26th Annual Education Symposium 2
... to Focus on G-Protein Coupled Receptors, BERWYN, ... discovery,company focused on developing pharmaceutical products targeting G-protein,coupled ... $24 million,Series A financing. Alta Partners and Healthcare ... syndicate that included New Enterprise Associates and,Polaris Venture ...
... GAINESVILLE, Fla., March 5 In a strange ... new, non-surgical infertility treatment started,reporting unusual side-effects: increased ... reproductive tract adhesions, caused,unexpected results in some patients ... physical therapist Belinda Wurn. (see, http://www.clearpassage.com ), ...
... have discovered an Antarctic fish species that adopts a ... week in the journal PLoS ONE, the online journal ... Antarctic Survey (BAS) and the University of Birmingham reveal, ... coriiceps effectively puts itself on ice to survive the ...
... Calif., March 5 "I have never,experienced greater satisfaction ... cells.", The quote, from Greg Smith, CEO, Mountain ... the storage of umbilical cord blood by,CorCell, Philadelphia, Pa., ... Mr. Smith continues: "The thought of possibly protecting ...
... entered into by,Airborne Health, Inc. - the maker of ... In that settlement, Airborne,Health, Inc. agreed to pay approximately ... California. The settlement has been reported in the,national media ... Airborne Health,Inc., But there is more to the ...
... Secretary of Health,Dr. Calvin B. Johnson met with ... to discuss Governor Edward G. Rendell,s plan to ... of uninsured adults,through his "Cover All Pennsylvanians" proposal., ... help prevent disease,successfully manage chronic diseases such as ...
Cached Medicine News:Health News:Trevena, Inc. Announces $24 Million Series A Financing 2Health News:Trevena, Inc. Announces $24 Million Series A Financing 3Health News:Surprise Orgasms Baffle Women Undergoing New Infertility Treatment 2Health News:Hibernation-like behavior in Antarctic fish -- on ice for winter 2Health News:Greatest Satisfaction Preserving Granddaughter's Cord Blood Stem Cells 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 2Health News:Information About The Airborne Health, Inc. Settlement, and Other Ongoing Litigation Alleging False and Deceptive Marketing Of Airborne(R) 3Health News:Health Secretary Stops in Erie County to Call for Health Insurance for all Pennsylvanians 2
... are an ophthalmologic medical device designed for ... -1.00 to -3.00 diopters.* When placed in ... central optical zone, the product reshapes the ... is composed of two prescription inserts, each ...
... is our most affordable basic centrifuge. The 614 is ... 614 is also the quietest small lab centrifuge on ... up to six (6) test tubes up to 15ml ... lid safety switch and is UL/CSA compliant. ...
... is a simple one, help physicians serve ... image, the physician is provided with significantly ... structures. This technical accomplishment is combined with ... The device features: ...
... Contour Eyelid Implants feature a proprietary ... of the ocular globe. The Contour ... in the eyelid because the tapered lower ... lower profile. Surfaces and edges of the ...
Medicine Products: